« Return to News | Awards & Advancement

Clinilabs selected for investigational medication study

Friday, July 15, 2011 10:43 AM

CRO Clinilabs has been selected to conduct a clinical research study on the effects of an investigational medication on the sleep of healthy volunteers.

This study uses an experimental model to assess the effects of an investigational medication on nighttime sleep and morning alertness in healthy volunteers.  President and CEO Dr. Gary Zammit said the use of experimental models and biomarkers are increasingly important in early-phase drug development. 

“The current study employs an experimental model of disturbed sleep that can be used as an assay to assess the potential therapeutic effects that drugs will have in patients with sleep disorders,” said Dr. Zammit. “The model will allow our client to determine if their drug should advance to later and more costly phases of testing.” 

The use of such models is likely to become more common as drug makers seek more efficient ways to test investigational medications.

Clinilabs is currently enrolling healthy male and female volunteers between the ages of 21 and 65 years who are not sleep deprived and who maintain a regular sleep/wake schedule. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.